Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab, Bevacizumab, and HAIC in Potentially Resectable Hepatocellular Carcinoma
NCT06405061Phase 2Suspended
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- May 2024
- Primary completion
- May 2027
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of adebrelimab in hepatocellular carcinoma (HCC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Started May 2024; status: suspended.
02
Drugs
adebrelimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06405061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06405061.